First

Atorvastatin
launchedin India
Meking lunde
GHeaiSTRONG! 350 Million patient days
with your care & experience globally
over 2 decades

Stoyhi Available in
17 countries

Assured Quality
with 301 Quality Checks (
& CFB Packaging

Start &Stay
with StoNar

IMS data as on Dec 2020

Storvas (A1orvastatin taltiurn 10,

20, 40 and 80 mg tablets)
DILATHONS AND USAGE Storvas is an
inhibitor for HMG-CoA reductase
bul with
fmultiple trsh tactors. Peduce teh risk of MI and stroke in
(statin) indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization
patients with type 2 diabetes without CHD, but with multiple risk factors. Reduce the risk of prOcedures, and angina in patients without CHO
proredures, hospttalzation for CHF, and in non-fatal Mi, fatal and non-tatal stroke, sevascularization
angina patients with CHD. Reduce elevated total-C, LOL-C,
aop B, and TG levels and increase HDL-C in adult
O ldftilal) afid ifized dyslipidefnia. keduce elevated 1G in
patient with patients with primary hyperlipidema (heterozygous tamilial and
(oFH). Feduce eleváted total-c, LDI-(
afnd apo B levels in hypertriglyceridemia and primary
dyslipoproteinemia. Reduce tolal-C and LOL-C in patients with homozygous Tamilial
boys and postmenarchal
girls, 10 to 17 years of age, with heterozygous familial hypercholestrolem13
ND ADIsIRAION D0se tafnge:10 to 20
rng once daily. Recornnended start dose: 10 or
20 mg once daily. Patients
hypercholestrolemia after failing an adequate tai ol diet
therapy. D0SAGE
y UO Uexplailied petSslent elevations in hepatic transaminase levels. requiring large LDI-C reduction (>45%) may start at 40 mg once daily. CONIRAINDICATONS: Active
O1
Pregnant and nursing wornen. Hypersensitivity to any coinponent of this medication. WARNINGS AND PRECAUTIONS
ae tases fiabdofnyo's15 witti àcute renal fatlure
secondary to myoglobinuria have been reported. In cases of
outoies hofifl ofing.
and
PeisIstent elevations in
hepatic transaninases can myopathy or
rhabdomyolysis, therapy should be temporarily withheld or discontinued. Liver
enzyme
Monitor liver enzymes before and during treatment. A higher incidence of
Du wSTOKE l14 wIllui the previous 6 irnontlis the Atorvastatin 80 ng occur.
Of
in hemorrhagic stroke was Seen in patients withoUt CHD
UEd group vs. placebo. DRUG INTERACIIONS Skeletal muscle effects
LOnCoritafily witfh cyclosporine,
tibtates, afd strong CYP3AA inhibitors
(e.g.,
(e.g, myopathy and thabdomyolysis): RiSKS InCiease when higlher doses are
inetded to be fnonloied. AbvtRSE REACIIONS Ihe no1 coninonly repoited larithronycin, intrconazole, HIV protease inhibitors). Possible inteiaction with Digoxin, Oral conttaceptives and
ale

adverse 1eaclions iainpicin hence levels

iasoptiaryngitis, atthtalgio, diarrhea, poi in
extuernity, old uiinaly tuatt inlecti0n. (incidence -20o) in
patients treated with atorvastatin in placebo-contiolled tiais tegardiess ol
Made in India causality were:
by:Sun Phatfnaceutical lndustuies Itd.
Full prescribing infornation
available on lequest

Vega Keepthe
SUN PHARMA division

Beatoi